Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DGI fiber tea is a functional beverage and dietary supplement formulated to support metabolic health, specifically by managing postprandial glycemic response. The product typically consists of a blend of soluble dietary fiber, such as resistant maltodextrin (often branded as Fibersol-2), and tea extracts (e.g., green tea or oolong tea). The primary mechanism of action involves the fiber's ability to increase the viscosity of the gastrointestinal contents, which slows the digestion and absorption of dietary carbohydrates, thereby attenuating spikes in blood glucose and insulin levels after meals. Additionally, tea polyphenols within the formulation may provide antioxidant benefits and potentially inhibit carbohydrate-digesting enzymes like alpha-glucosidase and alpha-amylase. It is marketed as a convenient dietary aid for individuals seeking to maintain healthy blood sugar levels or manage weight.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DGI fiber tea.